MUSTANG BIO, INC.

Mustang Bio reported a net loss of $1.07 million for the second quarter of 2026, an increase from $0.76 million in the same period last year. The company's cash and cash equivalents decreased to $15.15 million as of June 30, 2026, from $17.27 million at the end of 2025. Mustang Bio also disclosed non-compliance with Nasdaq's minimum bid price rule and anticipates continued operating losses and negative cash flows, though it believes it has sufficient cash for at least twelve months.

Mustang Bio, a clinical-stage biopharmaceutical company, received a Nasdaq delisting notice on April 15, 2026, for failing to meet the minimum bid price requirement. The company has until October 12, 2026, to regain compliance. For the first quarter of 2026, Mustang Bio reported a net loss of $0.96 million, an increase from $0.15 million in the prior year, with cash and cash equivalents at $16.3 million. The company continues to incur substantial operating losses and does not expect product sales revenue in the foreseeable future.

Mustang Bio, Inc. received a notice from Nasdaq on April 15, 2026, indicating non-compliance with the minimum bid price requirement. The company's common stock traded below $1.00 per share for 30 consecutive business days. Mustang Bio has been granted a 180-calendar day grace period, until October 12, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of ten consecutive business days.